# Glibenclamide (Dose to be Titrated From Starting Dose of 5mg om) Plus Rosiglitazone 4mg om (Increased to 8mg om After 6 Months) and vs Glibenclamide (Dose to be Titrated With Starting Dose of 5mg om) Plus Placebo, Administered to Patients With Type 2 Diabetes Mellitus

> **NCT01045590** · PHASE4 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 100 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** titration
- **DRUG:** titration

## Key facts

- **NCT ID:** NCT01045590
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-12
- **Primary completion:** 2006-02
- **Final completion:** 2006-02
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2012-06-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01045590

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01045590, "Glibenclamide (Dose to be Titrated From Starting Dose of 5mg om) Plus Rosiglitazone 4mg om (Increased to 8mg om After 6 Months) and vs Glibenclamide (Dose to be Titrated With Starting Dose of 5mg om) Plus Placebo, Administered to Patients With Type 2 Diabetes Mellitus". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01045590. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*